|
Age at first diagnosis of melanoma (years)
|
55
|
47–70
|
17–79
|
|
Time between primary diagnosis and first distant metastasis (months)
|
17
|
5–43
|
0–241
|
|
Time between start of combined immunotherapy and first staging (days)
|
69
|
49–80
|
12–108
|
|
Time between start of combined immunotherapy and onset of severe adverse events (days)
|
42
|
21–61
|
11–126
|
| | |
no. patients
|
%
|
|
Sex
|
|
Female
| |
16
|
46
|
|
Male
| |
19
|
54
|
|
Melanoma type
|
|
Cutaneous
| |
20
|
57
|
|
Occult
| |
6
|
17
|
|
Uveal
| |
4
|
11
|
|
Acral
| |
3
|
9
|
|
Mucosal
| |
2
|
6
|
|
BRAF mutation
|
|
BRAF v600 positive
| |
16
|
46
|
|
BRAF v600 negative
| |
19
|
54
|
|
Systemic treatment before combined immunotherapy
|
|
None – combined immunotherapy as first line
| |
22
|
63
|
|
Targeted therapy
| |
10
|
29
|
|
PD1 antibody
| |
3
|
9
|
|
LDH at start of combined immunotherapy
|
|
LDH elevated
| |
14
|
40
|
|
LDH normal
| |
21
|
60
|
|
Metastasis at start of combined immunotherapy
|
|
Presence of lung metastases
| |
19
|
54
|
|
Presence of brain metastases
| |
12
|
34
|
|
Presence of liver metastases
| |
10
|
29
|
|
AJCC (2017) stage
|
|
M1a/M1b
| |
11
|
31
|
|
M1c
| |
12
|
34
|
|
M1d
| |
12
|
34
|
|
Cycles of combined immunotherapy
|
|
1 cycle
| |
3
|
9
|
|
2 cycles
| |
7
|
20
|
|
3 cycles
| |
8
|
23
|
|
4 cycles
| |
17
|
49
|
|
Response to combined immunotherapy
|
|
Response
| |
15
|
43
|
|
-- complete response
| |
4
|
11
|
|
Progressive disease
| |
20
|
57
|
|
Adverse events CTCAE 3–4
| |
22
|
63
|
|
Origin of tissue sequenced
|
|
Lymph node metastasis
| |
15
|
43
|
|
Other metastasis
| |
18
|
51
|
|
Primary melanoma
| |
2
|
6
|
|
Status of tissue sequenced
|
|
Tissue therapy naïve
| |
31
|
89
|
|
Tissue pretreated
| |
4
|
11
|
